Information Provided By:
Fly News Breaks for September 30, 2016
ADHD
Sep 30, 2016 | 06:35 EDT
Piper Jaffray analyst Charles Duncan yesterday after the close downgraded Alcobra to Neutral and cut his price target for the shares to $3 from $10. The analyst cites the near-term increase in clinical risk and timeline uncertainty after the company's Metadoxine program was placed on full clinical hold by the FDA.
News For ADHD From the Last 2 Days
There are no results for your query ADHD